Estimating the effect of the run-in on the power of the Physicians' Health Study.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Statistics in Medicine

• Publication date

  1991-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/SIM.4780101010PMID 1947514
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The use of a run-in to enhance compliance.

  1990cited by this paper
• Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study.

  1988cited by this paper
• Patient compliance and the conduct and interpretation of therapeutic trials.

  1987cited by this paper
• Clinical Trials: Design, Conduct, and Analysis

  1986cited by this paper
• Successful program for recovery of dropouts to a clinical trial.

  1986cited by this paper
• Issues in the design and conduct of clinical trials.

  1984cited by this paper
• Design and methodological considerations in the National Cooperative Gallstone Study: a multicenter clinical trial.

  1981cited by this paper
• Ballistocardiography: Predictor of Coronary Heart Disease

  1968cited by this paper
• Surgery's relevance to an understanding of basic biology. Tissue repair and cellular regeneration.

  1967cited by this paper

• Factors associated with adherence to allocated treatment in the ASCEND trial: a mail-based randomised trial of aspirin and of omega-3 fatty acid supplementation in people with diabetes

  2026cites this paper
• Placebo nonresponders: An experimental investigation on their unreliability over time.

  2025cites this paper
• Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease

  2025cites this paper
• Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data

  2023cites this paper
• Effect of a Run‐In Period on Estimated Treatment Effects in Cardiovascular Randomized Clinical Trials: A Meta‐Analytic Review

  2022cites this paper
• Design and baseline characteristics of participants in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS).

  2022cites this paper
• Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial

  2022cites this paper
• Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial

  2022cites this paper
• Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample

  2021cites this paper
• Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial.

  2021cites this paper
• Concerning Pharmacogenetics, Pharmacogenomics and Personalized Medicine

  2021cites this paper
• Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK

  2021cites this paper
• Use of Run-in Periods in Randomized Trials.

  2020cites this paper
• Pre-randomization run-in periods in randomized controlled trials of chronic diseases: a methodological study.

  2020cites this paper
• Randomized clinical trials with run-in periods: frequency, characteristics and reporting

  2019cites this paper
• Kidney disease trials for the 21st century: innovations in design and conduct

  2019cites this paper
• A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study

  2018cites this paper
• Application and impact of run-in studies

  2018cites this paper
• Strategies to improve recruitment to randomised trials.

  2018cites this paper
• Haynes, R. et al. (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial

  2018cites this paper
• The Role of Omega-3 Fatty Acids and Aspirin in the Prevention of Cardiovascular disease in Diabetes and Biochemical effectiveness of Omega-3 Fatty Acids and Aspirin in the ASCEND trial

  2018cites this paper
• Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease: A Randomized Double-Blind Trial

  2018cites this paper
• ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes

  2017cites this paper
• Challenges in conducting clinical trials in nephrology Conduct Clinical Trials in Nephrology

  2017cites this paper
• Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.

  2017cites this paper
• Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference

  2017cites this paper
• Run-in Periods in Randomized Clinical Trials.

  2017cites this paper
• Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND)

  2016cites this paper
• ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours

  2016cites this paper
• Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data

  2016cites this paper
• Interpretation of the evidence for the efficacy and safety of statin therapy.

  2016cites this paper
• Clinical Trials ‐ Further Developments

  2014cites this paper
• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

  2013cites this paper
• Run-in phase III trial design with pharmacodynamics predictive biomarkers.

  2013cites this paper
• Design and rationale of the VIT amin D and Omeg A -3 Tria L (VITAL)

  2013cites this paper
• [Draft] Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drug and Biological Products

  2013cites this paper
• The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease.

  2012cites this paper
• Contains Nonbinding Recommendations Draft – Not for Implementation Guidance for Industry Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products

  2012cites this paper
• Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial.

  2012cites this paper
• Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.

  2012cites this paper
• Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.

  2012cites this paper
• Clinical trials of lipid-modifying agents:design considerations

  2011cites this paper
• The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

  2011cites this paper
• Prevention Trials

  2011cites this paper
• Intent-to-Randomize Corrections for Missing Data Resulting from Run-In Selection Bias in Clinical Trials for Chronic Conditions

  2011cites this paper
• Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.

  2010cites this paper
• Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B 12 vs Placebo on Mortality and Major Morbidity in Myocardial Infarction

  2010cites this paper
• Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

  2010cites this paper
• Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B 12 vs Placebo on Mortality and Major Morbidity in Myocardial Infarction

  2010cites this paper
• Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

  2010cites this paper
• Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B 12 vs Placebo on Mortality and Major Morbidity in Myocardial Infarction

  2010cites this paper
• Strategies to improve recruitment to randomised controlled trials.

  2010cites this paper
• Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B 12 vs Placebo on Mortality and Major Morbidity in Myocardial Infarction

  2010cites this paper
• Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.

  2010cites this paper
• Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial.

  2009cites this paper
• Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people

  2009cites this paper
• Vitamins E and C in the Prevention of Prostate and Total Cancer in Men

  2008cites this paper
• Randomized Controlled Trial Disease in Men : The Physicians ' Health Study II Vitamins E and C in the Prevention of Cardiovascular

  2008cites this paper
• Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.

  2008cites this paper
• Randomized Controlled Trial Cancer in Men: The Physicians' Health Study II Vitamins E and C in the Prevention of Prostate and Total

  2008cites this paper
• Antioxidant supplements for preventing gastrointestinal cancers.

  2008cites this paper
• Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.

  2008cites this paper
• Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.

  2008cites this paper
• MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial.

  2008cites this paper
• 6 chronic diseases: a systematic literature review

  2008influential citation
• Usefulness of a run-in period to reduce drop-outs in a randomized controlled trial of a behavioral intervention.

  2008cites this paper
• Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors.

  2007cites this paper
• Patient compliance and medical research

  2007cites this paper
• Reporting of Adherence to Medication in Recent Randomized Controlled Trials of 6 Chronic Diseases: A Systematic Literature Review

  2007influential citation
• Vom Nutzen und Nachteil von Run-in-Phasen für klinische Studien. Immer sinnvoll und ethisch vertretbar?

  2007cites this paper
• Run-in Period

  2007cites this paper
• Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain

  2005cites this paper
• “Why do they do that?”

  2005cites this paper
• Enhancing adherence in clinical research.

  2005cites this paper
• Physicians' Health Study

  2005cites this paper
• Antioxidant supplements for preventing gastrointestinal cancers.

  2004cites this paper
• Use of a run-in period to decrease loss to follow-up in the Contact Lens and Myopia Progression (CLAMP) study.

  2003cites this paper
• New Methods of Hormonal Contraception

  2003cites this paper
• Continuous Combination Oral Contraceptive Pills to Eliminate Withdrawal Bleeding: A Randomized Trial

  2003cites this paper
• Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians' Health Study.

  2002cites this paper
• Non‐compliance and its management in teenagers

  2002cites this paper
• Related to Randomized Trials of Primary Prevention

  2002cites this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cites this paper
• Special issues related to randomized trials of primary prevention.

  2002cites this paper
• Key design issues in primary prevention trials Adequate sample size Adequate duration of treatment and follow-up Achievement and maintenance of high compliance Run-in period Maximizing design efficiency Factorial design Selection of high-risk study population

  2002cites this paper
• Design of randomized trials.

  2002cites this paper
• The natural history of azathioprine compliance after renal transplantation.

  2001cites this paper
• Baseline Characteristics of Participants in the Women's Health Study

  2000cites this paper
• Antioxidant vitamin and mineral supplementation for preventing age-related macular degeneration.

  2000cites this paper
• Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials.

  2000cites this paper
• Inclusion of Older Women in Randomized Clinical Trials: Factors Associated with Taking Study Medication in the Fracture Intervention Trial

  2000cites this paper
• MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.

  1999cites this paper
• Run-in periods in randomized trials: implications for the application of results in clinical practice.

  1998cites this paper
• Concerns about run-in periods in randomized trials.

  1998cites this paper
• Education and debate

  1997cites this paper
• A personal view of some controversies in allocating treatment to patients in clinical trials.

  1995cites this paper
• Patient compliance and medical research

  1994cites this paper
• Adherence to Aspirin in the Prevention of Myocardial Infarction: The Physicians' Health Study

  1994cites this paper
• Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study.

  1994cites this paper
• A comprehensive algorithm for determining whether a run-in strategy will be a cost-effective design modification in a randomized clinical trial.

  1993cites this paper